Abalone hemocyanin blocks the entry of herpes simplex virus 1 into cells: A potential new antiviral strategy

Negar Talaei Zanjani, Monica Miranda-Saksena, Peter Valtchev, Russell J. Diefenbach, Linda Hueston, Eve Diefenbach, Mohd Fareed Mohd Sairi, Vincent G. Gomes, Anthony L. Cunningham, Fariba Dehghani

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

A marine-derived compound, abalone hemocyanin, from Haliotis rubra was shown to have a unique mechanism of antiviral activity against herpes simplex virus 1 (HSV-1) infections. In vitro assays demonstrated the dose-dependent and inhibitory effect of purified hemocyanin against HSV-1 infection in Vero cells with a 50% effective dose (ED50) of 40 to 50 nM and no significant toxicity. In addition, hemocyanin specifically inhibited viral attachment and entry by binding selectively to the viral surface glycoproteins gD, gB, and gC, probably by mimicking their receptors. However, hemocyanin had no effect on postentry events and did not block infection by binding to cellular receptors for HSV. By the use of different mutants of gD and gB and a competitive heparin binding assay, both protein charge and conformation were shown to be the driving forces of the interaction between hemocyanin and viral glycoproteins. These findings also suggested that hemocyanin may have different motifs for binding to each of the viral glycoproteins B and D. The dimer subunit of hemocyanin with a 10-fold-smaller molecular mass exhibited similar binding to viral surface glycoproteins, showing that the observed inhibition did not require the entire multimer. Therefore, a small hemocyanin analogue could serve as a new antiviral candidate for HSV infections.

Original languageEnglish
Pages (from-to)1003-1012
Number of pages10
JournalAntimicrobial Agents and Chemotherapy
Volume60
Issue number2
DOIs
Publication statusPublished - 1 Feb 2016

Fingerprint

Hemocyanin
Human Herpesvirus 1
Antiviral Agents
Membrane Glycoproteins
Virus Diseases
Glycoproteins
Protein Conformation
Vero Cells
Competitive Binding
Infection
Heparin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Talaei Zanjani, N., Miranda-Saksena, M., Valtchev, P., Diefenbach, R. J., Hueston, L., Diefenbach, E., ... Dehghani, F. (2016). Abalone hemocyanin blocks the entry of herpes simplex virus 1 into cells: A potential new antiviral strategy. Antimicrobial Agents and Chemotherapy, 60(2), 1003-1012. https://doi.org/10.1128/AAC.01738-15

Abalone hemocyanin blocks the entry of herpes simplex virus 1 into cells : A potential new antiviral strategy. / Talaei Zanjani, Negar; Miranda-Saksena, Monica; Valtchev, Peter; Diefenbach, Russell J.; Hueston, Linda; Diefenbach, Eve; Mohd Sairi, Mohd Fareed; Gomes, Vincent G.; Cunningham, Anthony L.; Dehghani, Fariba.

In: Antimicrobial Agents and Chemotherapy, Vol. 60, No. 2, 01.02.2016, p. 1003-1012.

Research output: Contribution to journalArticle

Talaei Zanjani, N, Miranda-Saksena, M, Valtchev, P, Diefenbach, RJ, Hueston, L, Diefenbach, E, Mohd Sairi, MF, Gomes, VG, Cunningham, AL & Dehghani, F 2016, 'Abalone hemocyanin blocks the entry of herpes simplex virus 1 into cells: A potential new antiviral strategy', Antimicrobial Agents and Chemotherapy, vol. 60, no. 2, pp. 1003-1012. https://doi.org/10.1128/AAC.01738-15
Talaei Zanjani N, Miranda-Saksena M, Valtchev P, Diefenbach RJ, Hueston L, Diefenbach E et al. Abalone hemocyanin blocks the entry of herpes simplex virus 1 into cells: A potential new antiviral strategy. Antimicrobial Agents and Chemotherapy. 2016 Feb 1;60(2):1003-1012. https://doi.org/10.1128/AAC.01738-15
Talaei Zanjani, Negar ; Miranda-Saksena, Monica ; Valtchev, Peter ; Diefenbach, Russell J. ; Hueston, Linda ; Diefenbach, Eve ; Mohd Sairi, Mohd Fareed ; Gomes, Vincent G. ; Cunningham, Anthony L. ; Dehghani, Fariba. / Abalone hemocyanin blocks the entry of herpes simplex virus 1 into cells : A potential new antiviral strategy. In: Antimicrobial Agents and Chemotherapy. 2016 ; Vol. 60, No. 2. pp. 1003-1012.
@article{c761175417f24b85ad507743eb2408a8,
title = "Abalone hemocyanin blocks the entry of herpes simplex virus 1 into cells: A potential new antiviral strategy",
abstract = "A marine-derived compound, abalone hemocyanin, from Haliotis rubra was shown to have a unique mechanism of antiviral activity against herpes simplex virus 1 (HSV-1) infections. In vitro assays demonstrated the dose-dependent and inhibitory effect of purified hemocyanin against HSV-1 infection in Vero cells with a 50{\%} effective dose (ED50) of 40 to 50 nM and no significant toxicity. In addition, hemocyanin specifically inhibited viral attachment and entry by binding selectively to the viral surface glycoproteins gD, gB, and gC, probably by mimicking their receptors. However, hemocyanin had no effect on postentry events and did not block infection by binding to cellular receptors for HSV. By the use of different mutants of gD and gB and a competitive heparin binding assay, both protein charge and conformation were shown to be the driving forces of the interaction between hemocyanin and viral glycoproteins. These findings also suggested that hemocyanin may have different motifs for binding to each of the viral glycoproteins B and D. The dimer subunit of hemocyanin with a 10-fold-smaller molecular mass exhibited similar binding to viral surface glycoproteins, showing that the observed inhibition did not require the entire multimer. Therefore, a small hemocyanin analogue could serve as a new antiviral candidate for HSV infections.",
author = "{Talaei Zanjani}, Negar and Monica Miranda-Saksena and Peter Valtchev and Diefenbach, {Russell J.} and Linda Hueston and Eve Diefenbach and {Mohd Sairi}, {Mohd Fareed} and Gomes, {Vincent G.} and Cunningham, {Anthony L.} and Fariba Dehghani",
year = "2016",
month = "2",
day = "1",
doi = "10.1128/AAC.01738-15",
language = "English",
volume = "60",
pages = "1003--1012",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Abalone hemocyanin blocks the entry of herpes simplex virus 1 into cells

T2 - A potential new antiviral strategy

AU - Talaei Zanjani, Negar

AU - Miranda-Saksena, Monica

AU - Valtchev, Peter

AU - Diefenbach, Russell J.

AU - Hueston, Linda

AU - Diefenbach, Eve

AU - Mohd Sairi, Mohd Fareed

AU - Gomes, Vincent G.

AU - Cunningham, Anthony L.

AU - Dehghani, Fariba

PY - 2016/2/1

Y1 - 2016/2/1

N2 - A marine-derived compound, abalone hemocyanin, from Haliotis rubra was shown to have a unique mechanism of antiviral activity against herpes simplex virus 1 (HSV-1) infections. In vitro assays demonstrated the dose-dependent and inhibitory effect of purified hemocyanin against HSV-1 infection in Vero cells with a 50% effective dose (ED50) of 40 to 50 nM and no significant toxicity. In addition, hemocyanin specifically inhibited viral attachment and entry by binding selectively to the viral surface glycoproteins gD, gB, and gC, probably by mimicking their receptors. However, hemocyanin had no effect on postentry events and did not block infection by binding to cellular receptors for HSV. By the use of different mutants of gD and gB and a competitive heparin binding assay, both protein charge and conformation were shown to be the driving forces of the interaction between hemocyanin and viral glycoproteins. These findings also suggested that hemocyanin may have different motifs for binding to each of the viral glycoproteins B and D. The dimer subunit of hemocyanin with a 10-fold-smaller molecular mass exhibited similar binding to viral surface glycoproteins, showing that the observed inhibition did not require the entire multimer. Therefore, a small hemocyanin analogue could serve as a new antiviral candidate for HSV infections.

AB - A marine-derived compound, abalone hemocyanin, from Haliotis rubra was shown to have a unique mechanism of antiviral activity against herpes simplex virus 1 (HSV-1) infections. In vitro assays demonstrated the dose-dependent and inhibitory effect of purified hemocyanin against HSV-1 infection in Vero cells with a 50% effective dose (ED50) of 40 to 50 nM and no significant toxicity. In addition, hemocyanin specifically inhibited viral attachment and entry by binding selectively to the viral surface glycoproteins gD, gB, and gC, probably by mimicking their receptors. However, hemocyanin had no effect on postentry events and did not block infection by binding to cellular receptors for HSV. By the use of different mutants of gD and gB and a competitive heparin binding assay, both protein charge and conformation were shown to be the driving forces of the interaction between hemocyanin and viral glycoproteins. These findings also suggested that hemocyanin may have different motifs for binding to each of the viral glycoproteins B and D. The dimer subunit of hemocyanin with a 10-fold-smaller molecular mass exhibited similar binding to viral surface glycoproteins, showing that the observed inhibition did not require the entire multimer. Therefore, a small hemocyanin analogue could serve as a new antiviral candidate for HSV infections.

UR - http://www.scopus.com/inward/record.url?scp=84957922920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957922920&partnerID=8YFLogxK

U2 - 10.1128/AAC.01738-15

DO - 10.1128/AAC.01738-15

M3 - Article

C2 - 26643336

AN - SCOPUS:84957922920

VL - 60

SP - 1003

EP - 1012

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -